Pancreatic Cancer Drug Combo Shows 92% Response Rate, Advances to Phase 3
TNGX has more than doubled off its 52-week low of $3.12.
Summary
Tango Therapeutics announced a 92% objective response rate for its vopimetostat and daraxonrasib combination therapy in pancreatic cancer, with no new safety signals. This exceptionally strong clinical data for a difficult-to-treat cancer significantly de-risks the program. The company plans to advance the combination into Phase 3, marking a major step towards potential commercialization and a transformative event for the company.
At the time of this announcement, TNGX was trading at $28.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.12 to $28.41. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.